Cargando…
Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels
Autores principales: | Rondon, Eliseo, Venkataraman, Ramesh |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297624/ https://www.ncbi.nlm.nih.gov/pubmed/16277704 http://dx.doi.org/10.1186/cc3798 |
Ejemplares similares
-
Trials stopped early for benefit? Not so fast!
por: Heffner, Alan C, et al.
Publicado: (2007) -
Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit
por: Amanullah, Shakeel, et al.
Publicado: (2004) -
Albumin and furosemide for acute lung injury
por: Khan, Asjad, et al.
Publicado: (2007) -
Procalcitonin-guided antibiotics in severe sepsis
por: Simon, Peter, et al.
Publicado: (2008) -
Hydroxyethyl starch in severe sepsis: end of starch era?
por: Estrada, Carlos A, et al.
Publicado: (2013)